Dr Amengual on Tazemetostat, Lenalidomide, and Rituximab in Relapsed/Refractory FL
August 23rd 2023Jennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).
Read More
Dr. Amengual on Vorinostat and Niacinamide in Lymphoma
December 19th 2013Jennifer E. Amengual, MD, assistant professor of medicine and developmental therapeutics, member, Center for Lymphoid Malignancies, Columbia University, discusses the potential of the combination of vorinostat and niacinamide as treatment for patients with diffuse large B-cell lymphoma.
Read More